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Abstract 
Review on CXCL17, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: DMC, Dcip1, UNQ473, VCC-1, 
VCC1 
HGNC (Hugo): CXCL17 
Location: 19q13.2 
Note 
CXCL17 was identified as a latest member of the 
C-X-C chemokine family in 2006 (Weinstein et al., 
2006; Pisabarro et al., 2006). Then, it was initially 
referred to by other names such as VEGF correlated 
chemokine 1 (VCC-1) (Weinstein et al., 2006) and 
dendritic and monocyte chemokine-like protein 
(DMC) (Pisabarro et al., 2006). VCC-1 and DMC 
were identified by cDNA microarray analysis and 
by structure-based protein analysis, respectively. 
DNA/RNA 
Note 
The CXCL17 gene is located on the long arm of 
chromosome 19, and it spans about 15 kb and 
includes four exons. 
Description 
Expression of the CXCL17 gene has been observed 
in several tissues. In human tissues, Northern blot 
analysis showed that CXCL17 is expressed in the 
trachea, stomach, lung, skeletal muscle, and the 
fetal lung (Pisabarro et al., 2006; Weinstein et al., 
2006). No Northern blotting signal is detected from 
the brain, heart, colon, thymus, spleen, kidney, 
liver, small intestine, placenta, and peripheral blood 
lymphocytes (Weinstein et al., 2006). Furthermore, 
investigation of CXCL17 expression using a 
comprehensive human gene expression microarray 
database showed that expression is restricted to 
mucosal sites including the digestive system, lung 
airways, the urethra, and several sites of the female 
reproductive system (Burkhardt et al., 2012). 
In mouse tissues, CXCL17 is expressed in the lung, 
thyroid, submaxillary gland, epididymis and uterus, 
with faint signals in the ovary and prostate 
(Weinstein et al., 2006). 
In rat tissues, real-time PCR using 22 different rat 
tissues demonstrated that CXCL17 was expressed 
mainly in the stomach, duodenum, lung, and 
salivary gland (Lee et al., 2013). 
Protein 
Description 
Human CXCL17 has a molecular mass of about 
13.8 kDa, and is a basic protein comprising 119 
amino acids. Mouse CXCL17 has a molecular mass 
of about 13.6 kDa, and is also a basic protein 
comprising 119 amino acids. 
Expression 
Extensive analyses of CXCL17-secreting or -
producing cells have yet to be performed. Some 
reports have demonstrated CXCL17 expression by 
immunostaining. Immunohistochemistry of the 
normal lung in adult humans demonstrated that 
CXCL17 was constitutively expressed on the 
bronchial and bronchiolar epithelium.  
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The CXCL17 gene (NM_198477.1). Full-length CXCL17 comprises about 15 kb and includes four exons and three introns. 
Squares: exon region; two-way arrow: intron region; green: coding region; yellow: untranslated region. 
 
 
Additionally, CXCL17 expression was also 
observed in the normal small intestine (duodenum) 
and colon.  
Specifically, CXCL17 production was localized to 
the villus and some crypt epithelial cells of the 
small intestine and colonic epithelial cells 
(Pisabarro et al., 2006).  
In mucosal tissues of the gastrointestinal tract, 
distinct cells were found that exhibited CXCL17-
positivity with unique cell surface markers and 
morphological characteristics, and these cells were 
identified as CD68+ macrophages and CD138+ 
plasma cells. 
Function 
Chemokines are generally classified into one of 
four groups on the basis of protein structure 
(cysteine residues), and can also be classified on the 
basis of functional differences (Zlotnik and Yoshie, 
2012).  
Chemokine groups based on functional 
characteristics include inflammatory, homeostatic, 
dual-function, plasma or precursor, and platelet 
chemokines.  
However, the functional and physiological role of 
CXCL17 remains unclear and has yet to be 
categorized.  
Interestingly, C-X-C chemokines are divided into 
two types on the basis of angiogenic potential: pro-
angiogenic types with an ELR motif and angiostatic 
types with a non-ELR motif.  
The ELR motif consists of the tripeptide glutamate 
(E)-leucine (L)-arginine (R). Pro-angiogenic types 
with an ELR motif which attract neutrophils are 
referred to as ELR+ chemokines, while angiostatic 
types that preferentially attract lymphocytes are 
referred to as ELR- chemokines (Vandercappellen 
et al., 2008; Strieter et al., 2005).  
In the case of CXCL17, the presence of the ELR 
motif has yet to be confirmed. However, CXCL17 
can be functionally classified as an ELR+ 
chemokine since CXCL17 shows pro-angiogenic 
function and neutrophil migration (Weinstein et al., 
2006; Vandercappellen et al., 2008; Zlotnik and 
Yoshie, 2012). 
Although the function and role of CXCL17 has 
been extensively investigated, its main receptor has  
 
 




Immunohistochemical analyses of clinical 
specimens showed that approximately 60% of cells 
were CXCL17-positive in human breast cancer 
(Matsui et al., 2012).  
Five out of seven mammary tumors showed 
considerable CXCL17 up-regulation (from 3-fold to 
more than 24-fold), in comparison with normal 
mammary tissues (Weinstein et al., 2006).  
RT-PCR analysis using 13 human breast cancer cell 
lines showed CXCL17 expression in 8 cell lines: 
MDA-MB-361, MCF7, BT-20, BT-474, HCC-
1419, HCC-1500, HCC-1937 and HCC-1954 
(Matsui et al., 2012). 
Hepatocellular carcinoma 
Note 
CXCL17 is expressed in hepatocellular carcinoma 
(HCC) in humans, but is not expressed in normal 
liver tissues.  
The average rate for CXCL17-positive HCC was 
83% (124 out of 148 samples) in an 
immunohistochemical study using clinical HCC 
specimens (Zhou et al., 2012).  
CXCL17 expression in HCC was much higher than 
that in adjacent non-cancerous tissue, and increased 
levels of CXCL17 expression were also shown in 
colon, gastric, breast, lung, bladder, and uterine 
cervical cancers (Zhou et al., 2012).  
In HCC cell lines, CXCL17-overexpressing HepG2 
cells showed increased cell proliferation compared 
to non-expressing control cells (Zhou et al., 2012). 
The SMMC7721 HCC cell line also showed similar 
results when CXCL17 was overexpressed (Mu et 
al., 2009).  
Moreover, colony formation, invasion and adhesion 
were promoted following forced expression of 
CXCL17 (Mu et al., 2009).  
When these cells were xenogenically transplanted 
into immunodeficient nude mice, tumor growth was 
significantly promoted in comparison with the 
control expression group.  
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Interestingly, whereas control HCC cells subjected 
to cisplatin treatment (100 µM) induced apoptotic 
morphological changes within 12 hours (e.g., cell 
budding, chromatin condensation, nuclear 
shrinkage, and cellular fragmentation), CXCL17-
expressing HCC cells resisted cisplatin-induced 
apoptotic cell death (Zhou et al., 2012). 
Colorectal cancer 
Note 
In critical specimens, expression of CXCL17 was 
50%-positive in human colorectal cancer (Matsui et 
al., 2012; Weinstein et al., 2006). In human 
colorectal cancer cell lines, four out of nine cell 
lines (HT-29, KM12, LoVo and COLO205) showed 
strong expression of CXCL17 mRNA (Matsui et 
al., 2012). In a mice model, xenotransplantation of 
CXCL17 overexpressing DLD-1 and SW620 cells 
into SCID mice resulted in enhanced tumor 
formation and an increase in the number of 
intratumoral vessels (Matsui et al., 2012). These 
tumors were associated with infiltrating CD11b+Gr-
1high neutrophil-like myeloid-derived cells. The 
neutrophil-like myeloid-derived cells were recruited 
at tumor sites by CXCL17. Indeed, SW620 cells 
transplanted with CXCL17-responding CD11b+Gr-
1high cells resulted in significantly enhanced tumor 
formation and angiogenesis compared to control 
cells. Furthermore, analyses of metastatic potential 
using in vivo luminescent imaging demonstrated 
that CXCL17-positive cells such as HT-29, KM12 
and COLO205 were hematogenous distant 
metastases, whereas CXCL17-negative cells such 
as DLD-1, SW620 and HCT-15 did not show any 
distant metastases (Matsui et al., 2012). 
Endometrial carcinoma 
Note 
Gene expression profiling using type I endometrial 
carcinoma patients demonstrated that 621 out of 
28869 genes were differentially expressed between 
tumor and normal tissues. Among these 621 genes, 
146 were up-regulated and 476 were down-
regulated in the tumor. One of the up-regulated 
genes was CXCL17, although additional biological 
analyses were not reported (Saghir et al., 2010). 
Pancreatic cancer 
Note 
In gene expression analyses using different stages 
of pancreatic cancers (intraductal papillary 
mucinous adenoma (IPMA) and intraductal 
papillary mucinous carcinoma (IPMC)), CXCL17  
expression was higher in IPMA compared to IPMC 
and normal ductal tissues (Hiraoka et al., 2011). In 
other words, this report suggested that expression of 
CXCL17 was induced at the early stage of 
carcinogenesis, and then decreased as 
carcinogenesis progressed.  
However, it has also been reported that CXCL17 
expression in human pancreatic cancer was much 
higher than in adjacent non-cancerous tissue (Zhou 
et al., 2012).  
In human pancreatic cancer cell lines, two out of 
five cell lines (KP-2 and BxPC-3) showed CXCL17 
mRNA expression (Matsui et al., 2012). 
Fibrosarcoma 
Note 
When mouse fibrosarcoma cells stably transfected 
with murine CXCL17 cDNA were injected 
subcutaneously into mice, these animals showed 
tumor growth retardation compared to parental cell 
transplantation (Hiraoka et al., 2011).  
It was subsequently demonstrated that abundant 
CD3+, CD4+ and CD8+ T cells and CD11b+CD11c+ 
dendritic cells infiltrated CXCL17-expressing 
tumors, suggesting that immune reactions were 
evoked in this animal model. 
Lung cancer 
Note 
Immunohistochemistry showed that about 30% of 
non-small cell lung carcinoma was CXCL17-
positive (Matsui et al., 2012). 
RT-PCR analysis also demonstrated that CXCL17 
mRNA expression was observed in three out of 
eight human lung cancer cell lines (NCI-H441, 
NCI-H1975 and NCI-H2228) (Matsui et al., 2012). 
Other tumors 
Note 
In RT-PCR analyses of human cancer cell lines, 
CXCL17 expression was demonstrated in one out 
of six renal cancer cell lines (RTK-2) and in two 
out of seven gastric cancer cell lines (MKN-45 and 
KATO III) (Matsui et al., 2012).  
Human melanoma cell lines investigated were all 
CXCL17-negative (Matsui et al., 2012). 
Tumorigenicity 
Note 
Tumorigenicity was examined in NIH3T3 cells that 
expressed CXCL17 cDNA. CXCL17-
overexpressing NIH3T3 cells were reported to form 
tumors in immunodeficient mice (Weinstein et al., 
2006; Matsui et al., 2012).  
However, CXCL17 expression itself did not induce 
focus formation and anchorage-independent cell 
growth using NIH3T3 cells and so CXCL17 lacked 
oncogenic transformation activity in vitro (Matsui 
et al., 2012). 
Angiogenesis 
Note 
In a two-dimensional assay using the mouse 
angioma endothelial cell line PY4.1, vascular tube 
formation in PY4.1 increased CXCL17 expression 






Atlas Genet Cytogenet Oncol Haematol. 2015; 19(2) 100 
levels 28-fold. Adenoviral overexpression of 
CXCL17 in human-derived vascular endothelial 
cells (HUVECs) resulted in up-regulation of 
vascular endothelial growth factor A (VEGF-A) 
(Weinstein et al., 2006). In another report, 
HUVECs exposed to recombinant CXCL17 
resulted in increased VEGF-A expression and cell 
migration (Matsui et al., 2012). Investigations of 
the human acute monocytic leukemia cell line THP-
1 showed that CXCL17-treated THP-1 cells 
resulted in increased levels of VEGF-A in the 
conditioned medium (Lee et al., 2013). 
Immunity 
Note 
CXCL17 has the ability to induce cell migration 
(chemotaxis) as is the case with chemokines. It has 
been demonstrated that some immune cells exhibit 
chemotactic cell migration through CXCL17. For 
example, in a transwell migration assay using 
human peripheral blood mononuclear cells 
(PBMCs), CXCL17 specifically induced migration 
of CD14+ monocytes and CD11c+ immature 
dendritic cells, but not of CD3+ T cells, CD19+ B 
cells, CD56+ natural killer cells or CD16+ 
neutrophils (Pisabarro et al., 2006; Hiraoka et al., 
2011). While CD14+ human monocyte-derived 
mature dendritic cells possessed CXCL17-induced 
chemotactic activity, immature Langerhans cells 
failed to acquire CXCL17-dependent chemotactic 
activity (Hiraoka et al., 2011). Furthermore, 
chemotaxis assays and flow cytometric analyses 
using murine splenocytes showed that CD11b+Gr-
1highF4/80- cells are specifically migrated in a 
manner dependent on CXCL17 (Matsui et al., 
2012). CXCL17-responding cells showed 
neutrophil-like myeloid-derived cell morphology 
and cell surface markers. 
Inflammation 
Note 
Chemokines can control the migration and 
localization of various cells in the body. However, 
some chemokines exhibit additional activities 
beyond the trafficking of cells. To date, CXCL17 
has also been found to possess antimicrobial and 
anti-inflammatory activity. The antimicrobial 
activity of CXCL17 was demonstrated using 
Escherichia coli, Staphylococcus aureus, 
Salmonella enterica serovar Typhimurium 14028s, 
Lactobacillus casei, and Pseudomonas aeruginosa 
(Burkhardt et al., 2012). This report demonstrated 
that CXCL17 possessed antimicrobial properties, 
unlike the case with CXCL8 (a representative 
chemokine that lacks antimicrobial activity). 
Moreover, the antimicrobial mechanism by which 
CXCL17 induces permeabilization of bacterial 
membranes was also demonstrated. On the other 
hand, the anti-inflammatory activity of CXCL17 
was demonstrated when cells pretreated with 
CXCL17 showed decreased inflammatory 
responses (Lee et al., 2013). J774 murine 
macrophage-like cells immediately express pro-
inflammatory genes such as IL-6, TNFα and iNOS 
when cells are stimulated with LPS. These 
cytokines mediate strong inflammatory responses. 
However, pretreatment with CXCL17 significantly 
reduces LPS-induced expression of pro-
inflammatory genes, and LPS-mediated 
inflammatory responses are attenuated. 
Others 
Note 
In a microarray-based whole-genome screening 
system using duodenal mucosa during acute 
cholera, expression of CXCL17 was up-regulated in 
cholera patients (Flach et al., 2007). In these acute 
cholera patients, mucosal CD8+ cells in the small 
intestine were localized in the lamina propria 
region. In contrast, these cells migrated from the 
lamina propria region to the epithelium in the 
convalescent stage. Details concerning the 
relationship between CXCL17 expression and 
changes in the localization pattern of the mucosal 
CD8+ cells remain to be determined. CXCL17 was 
produced in bronchoalveolar lavage fluids in 
patients with human idiopathic pulmonary fibrosis 
(IPF) (Burkhardt et al., 2012), suggesting that 
CXCL17 production may be associated with human 
pulmonary diseases. 
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